Skip to main content

Table 2 Best response after 1–2 cycles of the CDCAG therapy (N = 93)

From: Chidamide, decitabine, cytarabine, aclarubicin, and granulocyte colony-stimulating factor (CDCAG) in patients with relapsed/refractory acute myeloid leukemia: a single-arm, phase 1/2 study

Clinical response

N (%)

CR

24 (25.8)

CRi

19 (20.4)

PR

8 (8.6)

NR

38 (40.9)

ED

4 (4.3)

  1. Abbreviations: CR complete remission, CRi complete remission with incomplete blood count recovery, PR partial remission, NR no response, ED early death